Methotrexate Accord

Methotrexate, the active ingredient in Methotrexate Accord, is an antimetabolite (folate antagonist) presented as a sterile injectable for intraarterial, intramuscular, and intrathecal use. It treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, gestational trophoblastic disease and osteosarcoma in appropriate patients.

GNH USA supplies Methotrexate Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to strict quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and timely delivery across multiple continents.

Methotrexate is an antimetabolite used in autoimmune and oncologic conditions. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: limits skin cell proliferation and improves plaque appearance. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: suppresses tumor growth as part of combination chemotherapy. - Gestational trophoblastic disease: induces remission by targeting rapidly dividing trophoblastic tissue. - Osteosarcoma: contributes to tumor control when used in multimodal therapy.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or malaise - Oral mucosal ulceration (stomatitis) - Transient elevation of liver enzymes - Decreased white blood cell count (leukopenia) - Hair thinning or temporary alopecia

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis - Bone marrow suppression leading to pancytopenia - Pulmonary toxicity, including interstitial pneumonitis - Life‑threatening infections due to immunosuppression - Acute renal failure - Severe cutaneous reactions such as Stevens‑Johnson syndrome

Before initiating therapy, several safety considerations are essential. - Pregnancy: contraindicated; teratogenic risk is classified as Category X. - Liver function: monitor transaminases regularly; avoid use in pre‑existing severe hepatic disease. - Hematology: perform complete blood counts before and during treatment to detect myelosuppression. - Renal function: assess creatinine clearance; dose adjustment may be required in impairment. - Vaccinations: avoid live vaccines while on therapy. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several drugs that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate plasma levels and risk of toxicity. - Penicillins and other β‑lactam antibiotics: potentiate bone marrow suppression. - Sulfonamide antibiotics: may enhance hematologic toxicity.

Moderate Interactions (Monitor Closely): - Azathioprine: additive immunosuppressive effect; monitor blood counts. - Allopurinol: may increase methotrexate toxicity; adjust dose if necessary. - Proton pump inhibitors: can affect renal clearance; observe renal function.